Company intelligence / Profile preview

Mavatar

Stockholm, Sweden

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Mavatar has developed two flagship AI-driven platforms—Mavatar Discovery (for accelerating disease and drug research) and Mavatar Precision (for personalized treatment recommendations). The Discovery platform is in closed BETA with a public launch planned for June–September 2025. The Precision clinical decision support tool is under development with plans for FDA submission in 2026. No direct clinical trial results as the company provides enabling technology rather than therapeutics

Therapeutic areas: Other
Modalities: Data analyticsDigital twin modeling
Industry: Drug Discovery Services

Partnerships

No specific major pharmaceutical or biotech partnerships publicly disclosed as of June–June, but company collaborates with researchers, pharma companies, and institutions using its platforms

Beyond the preview

Go deeper on Mavatar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mavatar.

Explore the full profile